🎗️
Oncology
What the Latest Research Reveals
Data last updated: 32 studies cited
How this page is produced
Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This page is AI-generated and has not yet been reviewed by a clinician — it is not medical advice. Read how we build and check these pages.
2.5x
Higher COVID-19 mortality risk in cancer patients
— based on meta-analysis of 50,000+ patients
KEY FINDINGS
Cancer Mortality
+154%
95% CI: OR 2.54 (95% CI: 2.28-2.83)
Source [1]
Hematologic Malignancy
+57%
95% CI: OR 1.57 vs solid tumors (95% CI: 1.15-2.13)
Source [3]
Recent Chemotherapy
+64%
95% CI: HR 1.64 (95% CI: 1.36-1.99)
Source [6]
Treatment Delay
+6-13%
95% CI: Mortality increase per 4-week delay
Source [2]
Vaccine effectiveness of bivalent COVID-19 vaccination against reinfection in adults with cancer
22.2%
95% CI: 95% CI: 15.8-28.2%
Source [31]
Reinfection risk in bivalent vaccinated cancer patients
5.2%
Source [31]
Reinfection risk in unvaccinated cancer patients
8.4%
Source [31]
Proportion of cancer patients who received bivalent vaccines in the study
24.1%
Source [31]
Vaccination effectiveness in active radio- or chemo-therapy (RCT) subgroup during JN.1 wave
HR 0.68
95% CI: 95% CI 0.44-1.03
Source [32]
Active radio- or chemo-therapy (RCT) patients had higher severe COVID-19 rates than immunosuppressive medication or immunodeficiency groups
Higher rates of severe COVID-19
Source [32]
THE TIMELINE
Acute Phase
0-4 weeks
Subacute Phase
4-12 weeks
Chronic Phase
3-12 months
Long-Term
>12 months
Acute Phase
0-4 weeks
Higher inflammatory markers, earlier oxygen need
Key Event
Rapid progression to severe disease
Cancer Screening Reduction During Peak Pandemic
COVID-19 Pandemic87%
Baseline0%
Source: Kaufman et al., Health Affairs 2020 - mammography reduction at nadir
Reinfection Risk in Cancer Patients
General Population+Baseline
Cancer Patients+2-3x higher
Shorter Interval+4-6 months
“Immunocompromised patients show higher reinfection rates with shorter intervals”
THE HOPEFUL HORIZON
- ICI therapy does not increase COVID-19 severity - safe to continue[10]
- Vaccine efficacy 54-95% in cancer patients with proper dosing[18]
- Screening rates recovering to 75-90% of pre-pandemic levels[14]
- Surgical backlogs largely cleared by 2023
SOURCES
- [1]Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and COVID-19: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43-50. DOI (opens in new tab)
- [2]Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087. DOI (opens in new tab)
- [3]Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-2892. DOI (opens in new tab)
- [4]ElGohary GM, Hashmi S, Styczynski J, et al. The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2020. DOI (opens in new tab)
- [5]Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):893-903. DOI (opens in new tab)
See a problem with the Oncology research summary?
Send a source correction or freshness concern. We cannot provide personal medical advice through this site.
Report a correctionSHARE THIS INFORMATION
Share with someone who needs to know